Schnieders Capital Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.82M | Buy |
19,159
+2,925
| +18% | +$629K | 0.63% | 37 |
|
|
2026
Q1 | $3.53M | Buy |
16,234
+166
| +1% | +$36.8K | 0.56% | 44 |
|
|
2025
Q4 | $3.67M | Buy |
16,068
+677
| +4% | +$154K | 0.57% | 43 |
|
|
2025
Q3 | $3.56M | Sell |
15,391
-1,075
| -7% | -$219K | 0.64% | 44 |
|
|
2025
Q2 | $3.06M | Buy |
16,466
+789
| +5% | +$147K | 0.54% | 44 |
|
|
2025
Q1 | $3.28M | Sell |
15,677
-1,154
| -7% | -$224K | 0.7% | 37 |
|
|
2024
Q4 | $2.99M | Sell |
16,831
-9,795
| -37% | -$1.8M | 0.59% | 39 |
|
|
2024
Q3 | $5.26M | Buy |
26,626
+585
| +2% | +$109K | 1% | 28 |
|
|
2024
Q2 | $4.47M | Sell |
26,041
-494
| -2% | -$81.8K | 0.9% | 28 |
|
|
2024
Q1 | $4.83M | Sell |
26,535
-21
| -0.1% | -$3.62K | 1% | 27 |
|
|
2023
Q4 | $4.12M | Sell |
26,556
-5,843
| -18% | -$852K | 0.91% | 27 |
|
|
2023
Q3 | $4.83M | Sell |
32,399
-8
| -0% | -$1.17K | 1.08% | 26 |
|
|
2023
Q2 | $4.37M | Sell |
32,407
-92
| -0.3% | -$13.5K | 0.91% | 28 |
|
|
2023
Q1 | $5.18M | Sell |
32,499
-530
| -2% | -$81K | 1.16% | 24 |
|
|
2022
Q4 | $5.34M | Buy |
33,029
+4,193
| +15% | +$643K | 1.22% | 23 |
|
|
2022
Q3 | $3.87M | Buy |
28,836
+10,700
| +59% | +$1.54M | 1.02% | 29 |
|
|
2022
Q2 | $2.78M | Buy |
18,136
+166
| +0.9% | +$25.4K | 0.83% | 34 |
|
|
2022
Q1 | $2.91M | Buy |
17,970
+14
| +0.1% | +$2.03K | 0.69% | 38 |
|
|
2021
Q4 | $2.43M | Buy |
17,956
+1,045
| +6% | +$123K | 0.57% | 48 |
|
|
2021
Q3 | $1.82M | Sell |
16,911
-45
| -0.3% | -$5.14K | 0.49% | 51 |
|
|
2021
Q2 | $1.91M | Hold |
16,956
| – | – | 0.52% | 49 |
|
|
2021
Q1 | $1.83M | Buy |
16,956
+4
| +0% | +$428 | 0.55% | 45 |
|
|
2020
Q4 | $1.82M | Hold |
16,952
| – | – | 0.6% | 42 |
|
|
2020
Q3 | $1.49M | Sell |
16,952
-600
| -3% | -$56.5K | 0.56% | 47 |
|
|
2020
Q2 | $1.72M | Buy |
17,552
+150
| +0.9% | +$13.2K | 0.69% | 41 |
|
|
2020
Q1 | $1.33M | Sell |
17,402
-662
| -4% | -$56.4K | 0.64% | 45 |
|
|
2019
Q4 | $1.6M | Buy |
18,064
+170
| +1% | +$14.1K | 0.58% | 53 |
|
|
2019
Q3 | $1.35M | Sell |
17,894
-6,205
| -26% | -$425K | 0.55% | 58 |
|
|
2019
Q2 | $1.75M | Sell |
24,099
-2,400
| -9% | -$189K | 0.69% | 51 |
|
|
2019
Q1 | $2.13M | Sell |
26,499
-3,325
| -11% | -$272K | 0.91% | 40 |
|
|
2018
Q4 | $2.75M | Sell |
29,824
-1,152
| -4% | -$101K | 1.35% | 25 |
|
|
2018
Q3 | $2.93M | Sell |
30,976
-150
| -0.5% | -$14.2K | 1.2% | 29 |
|
|
2018
Q2 | $2.88M | Sell |
31,126
-1,290
| -4% | -$126K | 1.22% | 29 |
|
|
2018
Q1 | $3.07M | Sell |
32,416
-1,295
| -4% | -$142K | 1.32% | 23 |
|
|
2017
Q4 | $3.26M | Sell |
33,711
-2,070
| -6% | -$195K | 1.35% | 23 |
|
|
2017
Q3 | $3.18M | Buy |
35,781
+170
| +0.5% | +$12.9K | 1.39% | 24 |
|
|
2017
Q2 | $2.58M | Buy |
35,611
+1,550
| +5% | +$104K | 1.2% | 27 |
|
|
2017
Q1 | $2.22M | Sell |
34,061
-25
| -0.1% | -$1.57K | 1.06% | 31 |
|
|
2016
Q4 | $2.13M | Buy |
34,086
+970
| +3% | +$59.2K | 1.1% | 31 |
|
|
2016
Q3 | $2.09M | Sell |
33,116
-100
| -0.3% | -$6.47K | 1.17% | 30 |
|
|
2016
Q2 | $2.06M | Sell |
33,216
-2,730
| -8% | -$166K | 1.15% | 30 |
|
|
2016
Q1 | $2.05M | Sell |
35,946
-223
| -0.6% | -$12.4K | 1.21% | 29 |
|
|
2015
Q4 | $2.14M | Buy |
36,169
+1,537
| +4% | +$88.5K | 1.32% | 29 |
|
|
2015
Q3 | $1.88M | Buy |
34,632
+3,110
| +10% | +$202K | 1.3% | 26 |
|
|
2015
Q2 | $2.12M | Buy |
31,522
+1,000
| +3% | +$65.3K | 1.25% | 28 |
|
|
2015
Q1 | $1.79M | Buy |
30,522
+1,110
| +4% | +$67.1K | 1.08% | 34 |
|
|
2014
Q4 | $1.93M | Buy |
29,412
+5,460
| +23% | +$344K | 1.27% | 26 |
|
|
2014
Q3 | $1.38M | Sell |
23,952
-6,200
| -21% | -$344K | 1.02% | 31 |
|
|
2014
Q2 | $1.7M | Buy |
30,152
+9,500
| +46% | +$498K | 1.2% | 24 |
|
|
2014
Q1 | $1.06M | Sell |
20,652
-500
| -2% | -$25.3K | 0.99% | 35 |
|
|
2013
Q4 | $1.12M | Buy |
+21,152
| New | +$1.04M | 1.09% | 32 |
|
Other funds holding ABBV
Schnieders Capital Management's ABBV Position: Q2 2026 in Review
Schnieders Capital Management increased its AbbVie (ABBV) stake by 18% in Q2 2026, buying an estimated $629K and bringing the position to 19,159 shares worth $4.82M. The position accounts for 0.63% of the portfolio, ranked #37.
Schnieders Capital Management first reported a position in ABBV in Q4 2013 and has held it in 51 quarters since. The position peaked at $5.34M in Q4 2022. 4,194 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Schnieders Capital Management held 19,159 shares of AbbVie worth $4.82M as of Q2 2026.
- Schnieders Capital Management bought 2,925 AbbVie shares in Q2 2026, an estimated $629K.
- AbbVie made up 0.63% of Schnieders Capital Management's portfolio in Q2 2026, its #37 holding.
- Schnieders Capital Management first reported a position in AbbVie in Q4 2013 and has held it in 51 quarters since.
- Schnieders Capital Management's AbbVie position peaked at $5.34M in Q4 2022.
- 4,194 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Schnieders Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.